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AbstrACt
Introduction and aim Uncontrolled asthma is a global 
health challenge with substantial impact on quality of life 
(QoL) and overall healthcare costs. Unrecognised and/or 
unmanaged comorbidities often contribute to presence of 
uncontrolled asthma. Abnormalities in breathing pattern 
are termed dysfunctional breathing and are not only 
common in asthma but also lead to asthma- like symptoms 
and reduced QoL, and, in keeping with this, improvement 
with breathing normalisation. Evidence- based guidelines 
recommend breathing retraining interventions as an 
adjuvant treatment in uncontrolled asthma. Physiotherapy- 
based breathing pattern modification interventions 
incorporating relaxation have been shown to improve 
asthma- related QoL in primary care patients with impaired 
asthma control. Despite anecdotal reports, effectiveness 
of breathing retraining in patients referred to secondary 
care with incomplete asthma control has not been formally 
assessed in a randomised controlled trial (RCT). We aim to 
investigate the effect of breathing exercises on asthma- 
related QoL in patients with incomplete asthma control 
despite specialist care.
Methods and analysis This two- armed assessor- 
blinded multicentre RCT will investigate the effect 
of physiotherapist- delivered breathing retraining on 
asthma QoL questionnaire (MiniAQLQ) in addition to 
usual specialist care, recruiting from seven outpatient 
departments and one specialised clinic representing 
all regions of Denmark during 2017–2019. We will 
include 190 consenting adults with incomplete asthma 
control, defined as Asthma Control Questionnaire 6- 
item score ≥0.8. Participants will randomly be allocated 
to either breathing exercise programme in addition to 
usual care (BrEX +UC) or UC alone. BrEX compiles three 
physiotherapy sessions and encouragement to perform 
home exercise daily. Both groups continue usual secondary 
care management. Primary outcome is between- group 
difference in MiniAQLQ at 6 months. Secondary outcomes 
include patient- reported outcome measures, spirometry 
and accelerometer.
Ethics and dissemination Ethics Committee, Region 
Zealand (SJ-552) and Danish Data Protection Agency 
(REG-55–2016) approved the trial. Results will be reported 
in peer- reviewed scientific journals.
trial registration number NCT03127059; Pre-results.
bACkground
Asthma is a chronic, common, heterogeneous 
disease characterised by variable airflow 
obstruction due to airway inflammation and 
bronchial hyperreactivity.1 Globally, asthma 
affects around 300 million people. Dyspnoea 
is a very important symptom, which signifi-
cantly restricts physical activity and quality of 
life (QoL).1 2
Asthma- related QoL describes the subjec-
tive impairment conferred by asthma on a 
person’s life, and is a key patient- reported 
strengths and limitation of this study
 ► This trial investigates the effects of physiotherapist- 
delivered breathing pattern modification and relax-
ation on asthma- related quality of life in patients 
with incomplete asthma control despite attending 
specialist care, a resource demanding group where 
evidence for management strategies are lacking.
 ► The multicentre design including participants at sec-
ondary care centres in all regions of Denmark com-
paring a clinically relevant and low- cost intervention 
with usual care supports external validity.
 ► Participants and treatment providers cannot be 
blinded due to the nature of the intervention.
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outcome.3 It is impaired in most patients with asthma, and 
may be assessed by the validated MiniAsthma Quality of 
Life Questionnaire (MiniAQLQ).4 Several factors affect 
asthma- related QoL: (a) asthma- specific such as severity 
and type of asthma symptoms, (b) asthma- related such 
as triggers and comorbidities and (c) ‘patient- related’ 
factors, such as emotional stability, overall stamina, educa-
tion and income.5–7
Asthma- related QoL is only moderately associated with 
asthma control, and asthma control remains the key metric 
for assessing the impact of living with asthma.6 Asthma 
control is currently defined as absence of key symptoms 
and signs of asthma (dyspnoea or coughing during night- 
time or exercise, exacerbations, and emergency health-
care usage), and no asthma- related impairment of activity 
or QoL.2 A tool widely used to measure asthma control is 
the Asthma Control Questionnaire (ACQ), which is avail-
able in 5- item, 6- item or 7- item versions, where item 7 is 
lung function expressed as percentage of expected forced 
expiratory volume in first second (FEV1 % expected).8 9
More than 10% of the asthma population has difficult- 
to- treat asthma with poor asthma control despite substan-
tial pharmacological treatment (ie, Global Initiative 
for Asthma, GINA, steps 4–5).2 10 11 This subgroup uses 
high levels of asthma- related healthcare resources due 
to increased symptom burden, medication usage, preva-
lence of comorbidities, smoking, sick leave, higher exacer-
bation rates and emergency department visits compared 
with patients with asthma control.2 12 Likewise, individual 
costs to medication, unemployment, poorer education, 
sick leave, and early retirement are substantial too. True 
severe asthma is seldom the cause of difficult- to- treat 
asthma. Common causes are inadequate treatment (eg, 
adherence, inhaler technique), triggers (eg, smoking, 
allergens), erroneous asthma diagnoses or comorbidi-
ties (both: eg, non- asthma respiratory disease, obesity, 
rhinitis, cardiovascular diseases, dysfunctional breathing 
(DB), neuromuscular disease or poor cardiorespiratory 
fitness).2 13–17
Abnormalities in breathing pattern are usually referred 
to as DB. The extreme disordered breathing patterns range 
from fast and shallow to slow and deep. The first, for example, 
rate 20–40, thoracic breathing also known as hyperventila-
tion, and the latter, for example, rate 5–8, diaphragmatic 
and whole thorax breathing, large tidal volume close to 
total lung capacity resulting in high ventilation volume.18 19 
However, both patterns result in increased minute volume. 
A patient with disordered breathing pattern may sigh often 
to compensate for over- inflated lung and elevated tidal 
volume (eg, end of tidal volume over functional residual 
capacity, FRC) to achieve FRC (relaxation pressure of lung 
plus chest wall equals the atmospheric pressure).19 20 DB 
is well- recognised but ill- defined disorder that often coex-
ists with asthma but may be an isolated problem and cause 
persistent or intermittent dyspnoea, coughing, loss of voice, 
chest tightness, anxiety and fatigue.2 13 15 21 22 There is no 
consensus on diagnostic criteria.21 The Nijmegen Question-
naire (NQ) is the commonly used screening tool,22–24 and 
estimates a prevalence of DB of 25% in Danish patients with 
severe asthma.25 However, the use of the NQ as a screening 
tool for DB in asthma has been questioned,26 and the NQ 
does not predict a response to intervention in controlled 
trials of breathing retraining.27 28
In asthma, pharmacological treatment targets airway 
inflammation, bronchoconstriction and possible comor-
bidities. Non- pharmacological treatment focuses on 
reduction of airway inflammation by avoidance of trig-
gers, diet and physical fitness, and (in obese) weight 
reduction, to improve asthma control.2 29 Physiotherapy 
has gained increasing attention as part of asthma care as 
many patients with asthma explicit signs of DB pattern.15 30
Trained physiotherapists provide breathing exer-
cises (BrEX) including re- education or modification of 
the breathing pattern. This involves instructions that 
encourage nasal route of breathing, mainly diaphrag-
matic respiratory movement, and normalising respiratory 
rate and tidal volume.31–33
In controlled trials in people with mild and moderate 
asthma (GINA steps 1–3), BrEX are safe, reduce symp-
toms, improve QoL and asthma control, but does not 
change lung function parameters or airways inflamma-
tion.28 34–37 Interestingly, the clinical effect of BrEX is 
unrelated to baseline NQ scores.26
Recent systematic reviews of BrEX in moderate to severe 
asthma conclude that the methodological quality and 
poor methods descriptions leave insufficient evidence for 
a firm recommendation.1 32 38 39
A previous, well- performed pragmatic- designed trial 
investigated a similar intervention (delivered by a DVD 
or face- to- face by a single physiotherapist) in patients 
in primary care in UK.28 The Danish healthcare system 
shares many similarities with the British NHS: Free health 
service for all citizens, all patients have a general prac-
titioner (GP) who is the gate- keeper to secondary care. 
Asthma GINA steps 1–4 is the responsibility of the GPs, 
who can refer to the local hospital’s Respiratory Service 
in case of diagnostic uncertainty or lack of control. 
There are few multidisciplinary clinics for ‘difficult- to- 
control asthma’ in Denmark (total population 5.6 million 
inhabitants).
However, patients with more difficult to control asthma 
attending secondary, outpatient respiratory clinic have 
not to date been studied. Therefore, we decided to 
perform an adequately powered, randomised controlled 
clinical trial of well- defined BrEX in a well- characterised 
cohort of patients referred from GP due to lack of control 
and still having suboptimal control (ACQ6 score ≥0.8) of 
pulmonologist- diagnosed asthma after ≥2 consultations 
with a pulmonologist.
Thus, the present pragmatic multicentre trial will 
contribute to the existing (sparse) evidence on physio-
therapy in asthma concerning target group (secondary 
care) and intervention (multicentre), the latter improving 
external validity of our findings.
The aim of our randomised controlled trial (RCT) is 
to compare changes in the key patient- reported outcome 
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asthma- related QoL (MiniAQLQ scores) in patients 
undergoing a BrEX programme (three sessions and 
encouragement to do daily home exercise during 12 
weeks) in addition to usual specialist care (US) with 
patients receiving specialist care management. Second-
arily, we will investigate the effects of the intervention 
on important patient- reported outcomes, including lung 
function, gait distance and physical activity level.
MEthods And AnAlysEs
trial design
The trial is designed as a randomised, controlled, assessor- 
blinded multicentre superiority trial with two parallel 
groups with a primary endpoint of change in asthma- 
related quality of life (MiniAQLQ) at 6 months from initi-
ating the intervention, that is, 12 weeks after intervention 
period.
The benefits achieved at 6 months are hypothesised to 
be maintained at 12 months.
Main trial information is presented in online supple-
mentary file table S1.
The trial protocol conforms to the Standard Protocol 
Items: Recommendations for Interventional Trials 
(SPIRIT),40 and the Template for Intervention Descrip-
tion and Replication (TIDieR) will be used.41 The 
schedule of enrolment, interventions and assessments is 
shown in figure 1.
The trial is registered on 26 April 2017. Enrolment 
started at the first centre on 26 April 2017 and at the 
last centre in January 2019. A much lower recruitment 
rate than expected were observed in the first months of 
the trial and the following actions were taken: inclusion 
criteria were modified (Protocol Version 2.4, see Partic-
ipants), additional recruiting centres were initiated in 
March 2018, October 2018, and January 2019 (Protocol 
Versions 2.4–2.6, March 2018–January 2019), and based 
also on high retention rate, the sample size was revised 
based on updated power calculation in May 2019. We 
expect to end recruitment in October 2019.
Patient and public involvement
Participants in a pilot study on breathing retraining 
in asthma gave formal feedback on the intervention 
including information, patient instruction and follow- up 
(KH Andreasson, ST Skou, M Thomas, U Bodtger, 2017, 
‘Breathing Exercise pilot study’, unpublished).
Participants
The target population is patients with physician diagnosed 
and specialist confirmed asthma, including patients with 
fixed airway obstruction, cough- variant asthma or other 
forms without current evidence of variable airflow obstruc-
tion,42 and incomplete asthma control despite specialist- 
provided asthma care and regular use of moderate- dose 
to high- dose inhaled steroids with or without a second 
controller (GINA steps 3–5). The diagnosis of asthma is 
not simple, and variable airflow limitation can be difficult 
to demonstrate in patients currently on treatment.14 43 
Restricting the trial to those able to display physiological 
reversibility on treatment at recruitment into the trial 
would have resulted in a biassed and unrepresentative 
sample.
Danish respiratory outpatient clinics at Naestved, 
Roskilde, Bispebjerg, Aalborg, Hvidovre, Silkeborg 
and Odense hospitals, and the private Allergy & Lung 
Clinic, Elsinore (Allergi og Lungeklinikken Helsingør) 
will recruit consecutively during a 30- month inclusion 
period. Recruitment is expected to be finalised 31 
October 2019.
The recruitment target is 190 participants with incom-
plete asthma control, randomly allocated 1:1 to inter-
vention or control groups. At recruitment, ACQ6 ≥1.5 is 
used to identify participants with uncontrolled asthma. 
Modification was done 1 January 2018 to improve inclu-
sion rates: participants will need to have an ACQ6 score 
≥0.8 and to be in a stable phase of their asthma defined 
as no treatment changes in the month preceding rando-
misation to be randomised, while still having incomplete 
asthma control.
Inclusion criteria
 ► Referred from GP to a secondary, outpatient respira-
tory clinic for lack of asthma control.
 ► Asthma diagnosed by a pulmonologist.
 ► ≥2 doctor visits at a specialised, pulmonologist- lead 
asthma clinic.
 ► Age≥18 years.
 ► ACQ6 score ≥0.8.
 ► Willing and able to give written informed consent.
 ► Speaks, reads and understands Danish.
Exclusion criteria
 ► Trained in breathing exercises by physiotherapist last 
6 months.
 ► Pregnancy.
 ► Any severe disease as judged by the responsible 
physician.
 ► Participating in another respiratory interventional 
research project.
recruitment procedure and consent
The trial flow is outlined in figure 2. Written advertise-
ments in the clinics pre- inform patients on the possi-
bility of trial participation to motivate participation. The 
respiratory nurse or the pulmonologist will enrol eligible 
participants during the scheduled visit (which routinely 
includes ACQ6 scoring). The nurse will provide the initial 
oral and written trial information, and the pulmonologist 
will screen for eligibility. The participant will receive thor-
ough verbal and written trial information and will have to 
return for a separate visit where a nurse or a physiother-
apist will provide detailed information on the trial and 
respond to participant queries before written informed 
consent is obtained. Consent paper form, online supple-
mentary file S2. If the enrolment rate is inadequate to 
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Figure 1 The figure details the schedule of enrolment, interventions and assessments of BEAT DB trial in accordance with 
the Standard Protocol Items: Recommendations for Interventional Trials template.40 BEAT DB trial: this acronym is used in 
ClinicalTrial.gov registration. aPrimary endpoint is at 6 months follow- up. bData collection of medication usage from baseline 
before allocation throughout until 12 months after allocation will be done at 12- months follow- up. BEAT DB, Breathing Exercises 
in Asthma Targeting Dysfunctional Breathing; PROM, patient- reported outcome measures.
meet the recruitment target, more centres will be invited 
to participate.
randomisation procedure and concealment of allocation
After completion of baseline assessment, participants will 
randomly be allocated to UC with or without BrEX in a 
1:1 allocation ratio by computer- generated randomisa-
tion using EasyTrial (EasyTrial APS, Aalborg, Denmark) 
in fixed blocks of four stratified by centre to assure equal 
size of groups at the seven centres. The chief investigator 
and all project workers will be blinded to the generation 
sequence. The nurse will activate the EasyTrial randomi-
sation function to reveal the allocated group for each 
individual participant. This information will be forwarded 
to the participants by e- mail sent from EasyTrial. After 
allocation, the chief investigator will be informed and will 
ask the local physiotherapists to invite participants in the 
BrEX +UC group to initiate the intervention.
blinding
The nature of the trial precludes blinding of partici-
pants or the physiotherapists delivering BrEX. Outcome 
assessors are blinded to the randomisation result, and 
participants will be reminded not to disclose their treat-
ment allocation to the outcome assessor. Nurses who will 
perform extraction of clinical data from medical reports, 
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Figure 2 Patient flow through the RCT BEAT DB trial. Consolidated Standards of Reporting Trials (CONSORT) flow diagram 
2010. BEAT DB, Breathing Exercises in Asthma Targeting Dysfunctional Breathing; ACQ6, asthma control questionnaire; BrEX, 
breathing exercises; MiniAQLQ, miniasthma quality of life questionnaire; RCT, randomised controlled trial; UC, usual specialist 
care.
and the statistician who will perform the analyses will also 
blinded to the allocation.
Blinded results (presented as group A compared with 
group B) will be presented to the research group, who 
will interpret the blinded results and prepare two alterna-
tive conclusions, prior to unblinding of the trial results.44
Interventions
At baseline, all participants will receive individual instruc-
tion in optimal inhalation technique by a respiratory 
nurse, who will also encourage the participant to use 
online video instructions.45
As the design is a pragmatic ‘real- world setting’ trial 
without standardisation of asthma therapy, the pharma-
cological treatment will be the choice of the responsible 
respiratory specialist, including changes, discontinuation 
or add- on of any treatment/combination. Treatment 
with positive expiratory pressure devices is not prohib-
ited. The patient will be randomised to either usual care 
with Breathing Exercises (BrEX +UC) or usual care alone 
(UC).
Breathing Exercises (BrEX)
BrEX consists of three physiotherapist- sessions with dura-
tion of 60 min (initial session=week 1) and 30 min (at 
weeks 4 and 9, ± 7 days).
BrEX session one is t1 in the group of usual specialist 
care with BrEX (BrEX +UC) figure 1.
The participant will be encouraged to do 10 min of 
home exercise twice daily.32 The entire intervention 
combines elements of the Papworth method46 and the 
Buteyko technique.47
Key points in the intervention are
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Table 1 Overview of the BrEX intervention
Items Description
1. Brief name BrEX (Breathing EXercises).
2. Why Previous studies showed the feature included in BrEX to be essential for persons with dysfunctional 
breathing and asthma
The BrEX is simple and requires no devices to perform but fits in daily living. The goal of the 
intervention is that the patient incorporates an ideal breathing pattern and that this pattern becomes 
automated
3. What materials The patient will be provided written materials with illustrations of elements of BrEX, including the 
home exercises. The physiotherapists will be provided a manual, including a schedule of anticipated 
progression
4. What procedure Each BrEX session will include an initial interview (online supplementary file S4, 12- item interview 
list) and an observation of the breathing pattern (table 3).
Features of BrEX are breathing pattern modification in rest and combined with physical activity and 
relaxation, breath holding exercise, handling of uncontrolled coughing, frequent sighing or yawning 
and patient education
5. Who provides BrEX will be provided by physiotherapists, who are trained in the BrEX intervention at a mandatory 
10- hour introduction, followed by thorough written information and telephone support (training 
and support given by the chief investigator), and have at least 1 year of experience in pulmonary 
physiotherapy
6. How BrEX will be delivered individually and face- to- face
7. Where In outpatient departments of physiotherapy at seven public hospitals in Denmark
8. When and how much A 12- week intervention period featuring three physiotherapy sessions delivered in week 1, 4 and 9 
(±7 days); the initial session will last for 60 min, and others for 30 min. Participants will be asked to 
do 10 min of home exercise twice daily throughout the 12 weeks
9. Tailoring BrEX will be individualised in pace of progression and combinations, or of regression and simplicity 
according to interview at each session start and observations during the session
10. Modifications N/A. Modifications will be reported (if any)
11. How well (planned) Besides the introduction, the physiotherapists will adhere to a BrEX manual. Participants will be 
filling out a training diary
12. How well (actual) N/A. This will be reported in the primary paper
This description is in accordance with the Template for Intervention Description and Replication, Hoffmann et al., 2014.41
BrEX, Breathing EXercises; N/A, Not applicable.
 ► Modification/normalisation of respiratory rate and/
or depth of breath by rhythmic, nasal inspiration, and 
diaphragmatic breathing, by long expiration, and 
by breath holding at FRC.32 46 47 Uncontrolled, non- 
phlegm coughing and frequent sighing are often seen 
in patients with disordered breathing pattern. The 
participant will be trained to reduce sighing and/or 
coughing by a suppression- technique.48
 ► Relaxation,32 46 especially of the neck, jaw, tongue and 
shoulders. We will emphasise the lowering of muscle 
tone in these areas and boost the feeling of gravity. 
The participant will be asked to ‘let go’ to get full 
support from the surroundings (pillow, plint, chair 
and ground) to increase feeling of being carried.
 ► Use of the breathing modification during walk and 
other physical activities.32 46
 ► Daily home exercise of BrEX.
The participant will receive a booklet covering all exer-
cises in text and illustrations, theoretical information 
about breathing patterns and modification, and a page 
designated for an individualised home programme speci-
fied by the treating physiotherapist.
See TIDieR table (table 1) and Supplementary note for 
details on the BrEX intervention (online supplementary 
S3), and 12- item interview list (online supplementary S4). 
Danish version of the participant booklet and an English 
translation will be available on request, when the trial 
data collection has finished.
Usual specialist care
Participants in both groups will receive UC, which will be 
provided at the discretion of the responsible pulmonol-
ogist based on the individual needs of the participant’s 
severity of disease and current level of asthma control. 
The UC is not a uniform intervention neither in contents 
nor in time spent (range 15–30 min), number of visits, 
nor visit intervals. The choice of pharmacotherapy is 
supported by step- up and step- down guidelines.2
The UC without BrEX group will be the control group 
in the trial and baseline date equals t1 in this group 
figure 1.
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Table 2 Overview of data collection in BEAT DB
Baseline
3 
months
6 
months
12 
months
Primary endpoint
  MiniAsthma Quality 
of Life Questionnaire 
(MiniAQLQ)*
@ @ @ @
Secondary endpoints
Patient- reported information
  Asthma Control 
Questionnaire (ACQ6)
@ @ @ @
  Nijmegen Questionnaire 
(NQ)
@ @ @ @
  Hospital Anxiety and 
Depression Scale 
(HADS)
@ @ @ @
  EuroQol- 5D (EQ- 5D- 5L) @ @ @ @
  Global Perceived Effect 
rate (GPE)
N/A @ @ @
  Patient Acceptable 
Symptom State (PASS)
N/A @ @ @
  Treatment Failure (TF) N/A @ @ @
  Smoking status @ @ @
  Socio- economic Status 
(SES)†
@
  Foster Score @ @
Anthropometric
  Gender @
  Age @
  Height, cm @
  Weight, kg @
  Body Mass Index (BMI) @
Register data
  Medication (treatment 
step 1–5)‡
@ @ @
  Comorbidity @ @ @
  Scheduled and acute 
medical visits (prev.6mo)
@ @
  Adverse events (AEs) N/A @ @ @
  Adherence N/A @
Functional capacity
  6 min Walk Test 
(6MWT)§
@ @
  Count Scale (CS) @ @
  Breath Holding Time 
(BHT)
@ @
  Respiratory pattern 
observation
@ @
Physical activity (SenseWear) average of 6 days¶
  Total energy expenditure 
(TEE), kJ (daily avg)
@ @ @
  Average METs (daily 
avg)
@ @ @
  Physical Activity Level 
(PAL) (daily avg)
@ @ @
Continued
data collection procedure and retention
Data will be collected at baseline (t1) and at 3, 6 and 12 
months (t2−t4). Overview of outcome collection is showed 
in table 2. Before RCT initiation, all assessors will be intro-
duced to, trained in, and supervised in the assessment 
procedure by the chief investigator. All assessors will be 
provided trial- specific assessment manuals, which have 
been tested in a pilot study (KH Andreasson, ST Skou, 
M Thomas, U Bodtger, 2017, ‘Breathing Exercise pilot 
study’, unpublished).
Patients- reported outcome measures (PROM) will be 
collected using online questionnaires in EasyTrial. Partic-
ipants will receive invitation and links by e- mail, and—if 
necessary—an SMS reminder 2 weeks later (t1- t4 plus 2 
weeks).
SenseWear (SW) data (accelerometry) will be extracted 
and entered by a research assistant not involved in any 
clinical parts of the trial.
Objective assessments will be done at the hospitals at 
baseline and at 6- month follow- up (±4 weeks) following 
a standardised procedure. The assessor will manually 
complete a datasheet, which will be entered as an elec-
tronic CaseReportForm in EasyTrial later.
The 6- month follow- up visit (t3) will be planned by 
phone with the participant by a coordinating research 
assistant. Two days before the scheduled follow visit, the 
participant will receive standard reminders by e- mail and 
SMS. If the visit is not completed, no matter the cause, 
the coordinating research assistant will contact the partic-
ipant by phone to reschedule the visit within the pre- 
specified time frame of maximally +4 weeks.
Participants will be prompted to complete 3- month and 
12- month follow- ups every second week until completion, 
reminders sent as SMS and e- mails after 2 weeks, and a 
phone call after 4 weeks.
If a participant discontinues the assigned allocation 
without withdrawing the consent, we will prompt him/her 
to remain in the trial that is, to complete the remaining 
follow- up visits/online questionnaires.
Reasons for non- adherence (eg, lack of interest, comor-
bidity reasons, exacerbation, emigration) and for non- 
retention (consent withdrawal, lost to follow- up) will be 
recorded.
outcomes
Demographic data will be collected at baseline: gender, 
age, body mass index, smoking status and socioeconomic 
status (educational level, work status, and income).
Primary outcome
Primary outcome is the between- group mean change 
in MiniAsthma Quality of Life Questionnaire (MiniAQLQ) 
from baseline to 6- month follow- up.4 MiniAQLQ is a vali-
dated, 15- item disease- specific PROM on experiences 
in symptoms, activity limitation, emotions and envi-
ronment during the previous 2 weeks. A 7- point Likert 
scale (1=maximum impairment; 7=no impairment) is 
used, and MiniAQLQ- score is the mean of all items. In 
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Baseline
3 
months
6 
months
12 
months
  Number of Steps (daily 
avg)
@ @ @
Lung parameters**
  Expiratory volume in 
first second (FEV1)
@ @
  Forced vital capacity 
(FVC)
@ @
  Ratio (FEV1/FVC) % of 
predicted
@ @
  FEV1 % of predicted @ @
  Peak expiratory flow 
rate (PEF)
@ @
  Maximal Inspiratory 
Pressure (MIP)
@ @
*Primary outcome is MiniAQLQ at 6 month follow- up.
†SES includes educational level, annual family income, work status.
‡Reliever and controller medication.
§Including Borg CR10.
¶Subgroup will be measured. 3 month follow- up only until April 2018.
**Reference values for spirometry: GLI2012.
BEAT DB, Breathing Exercises in Asthma Targeting Dysfunctional 
Breathing; METs, metabolic equivalents; N/A, Not applicable.
Table 2 Continued
moderate to severe asthma cohorts, MiniAQLQ has good 
reliability (ICC 0.83–0.86) and strong validity (criteria 
validity to AQLQ, r≥0.80; construct validity against ACQ, 
r=0.69).4 49 The Danish version of MiniAQLQ is validated 
linguistically, although cultural adaptation is missing.50 51
Secondary outcome measures
Secondary (continuous) outcome measures are the 
between- group mean change for each. All secondary 
outcomes will be considered supportive of the primary 
outcome, that is, conclusions will only be guided by the 
primary outcome.52 53
Patient-reported outcomes
ACQ6 is the 6- item questionnaire version on asthma 
control addressing five symptoms using a 7- point Likert 
scale (0=fully controlled; 6=severely uncontrolled), and 
reliever medication use (0=No use; 6=More than 16 
puffs most days) during the previous 7 days. Test–retest 
reliability of ACQ is excellent (ICC 0.83–0.90).8 9 ACQ6 
is valid in moderate to severe asthma; Cronbach’s α is 
0.86 (KH Andreasson, U Bodtger, ST Skou, M Thomas, 
J Comins, 2019, ‘Rasch validation of the Asthma Control 
Questionnaire’, unpublished results). ACQ score <0.75 
corresponds to well- controlled asthma, ACQ score ≥1.5 
denotes uncontrolled asthma, whereas ACQ from 0.75 to 
1.5 correspond to incomplete asthma control or partly 
controlled asthma.2 8 54
NQ is a reliable 16- item screening questionnaire 
designed to assess subjective sensations compatible with 
hyperventilation during previous 7 days.23
Hospital Anxiety and Depression Scale (HADS) contains 
seven items concerning anxiety, and seven concerning 
depression and uses 4- point Likert scales; a low score indi-
cates least mental health problems.55 Asthma and disor-
dered breathing pattern are known as associated with 
anxiety and depression.56 57
Global perceived effect (GPE) rate will be used as a retro-
spective evaluation of effect of asthma- related QoL as well 
as asthma control on a 7- point Likert scale.58 59 This global 
transition rating enables investigation of the validity and 
the interpretability of the primary outcome.59 60 This will 
be followed by the dichotomous Patient Acceptable Symptom 
State (PASS) that evaluates treatment success from the 
participant’s perspective related to level of asthma- related 
QoL and to asthma control.61 If the participant considers 
the symptom state to be ‘non- acceptable’, the partici-
pant will be asked whether he/she considers the state so 
unsatisfactory that Treatment Failure (TF) has occurred, 
answered by ‘yes’ or ‘no’. GPE, PASS and TF will be used 
at all follow- ups.
EuroQol- 5Dimension is a generic QoL tool consisting of 
a 5- dimension descriptive index (ranging from −0.59 to 
1.00) and a Visual Analogue Scale (ranging from 0 to 
100) describing self- perceived health status.62 63
Foster Score will be used to define the numbers of days 
(0–7) per week that the participant reports having taken 
his/her medication as prescribed.64
Objective performance outcomes
Physical activity level (PAL), metabolic equivalents, 
numbers of steps, and total energy expenditure (TEE) 
will be measured by a two axial accelerometer (Sence-
Wear, SW) (BodyMedia SenseWear, Pittsburgh, PA, USA) 
monitoring activity during 6 days.65 This is measured 
in all participants included May 2017–May 2018, here-
after only in participants from Naestved and Hvidovre 
Hospitals.
Functional capacity will be measured by 6 min Walk Test 
(6MWT). The 6MWT is a validated measure of response 
to physical activity intervention in respiratory research.66
Dyspnoea level will be measured before and after 
6MWT. To rate perceived dyspnoea the validated Borg 
CR10 will be used,67 as well as the Count Scale (CS).68 CS 
implies that the participant loudly counts starting from 
one to as high as possible at a constant speed of 2 counts 
per second, guided by a metronome, during one exhala-
tion from maximum inspiratory level.
Breathing pattern observation during 60 s, following a non- 
validated 10- item observational list assesses the respira-
tory pattern at rest. See table 3.
Breath Holding Time (BHT)69 will be measured in 
seconds from respiratory resting position (eg, FRC) until 
first involuntary respiratory muscle motion.
Spirometry (MedikroPro, M915, OY Finland) will be used 
to measure FEV1, forced vital capacity (FVC), FEV1/FVC 
ratio and peak expiratory flow rate.70 Predicted values will 
be calculated using GLI2012.71
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Table 3 Breathing pattern, 10- item observational list
Items observed for 60 s
  Respiration frequency RF:
  Rhythmic respiration Yes No
  Inspiration initiated upper thorax Yes, only Yes, partly No
  Inspiration initiated by diaphragm Yes, only Yes, partly No
  Nasal inspiration Yes, only Yes, partly No
  Clearing of throat (cough slightly) Number:
  Sighing (solitary large inhalation 
and exhalation)
Number:
  Yawning Number:
  Coughing (non- productive) Number:
  Bodily movement Yes No
Method
  The participant is at rest in sitting position.
  The observer sits a little beside the viewpoint of the participant. 
The observer sits facing the participant, uses a time watch, and 
follows instruction:
  Introduce to the participant:
  I will observe your breathing pattern for 1 min
  I will inform you, when the minute starts
  You are supposed to sit calm
  We are not allowed to talk meanwhile
  Start the time watch after a participant’s expiration
  Observe and judge subjectively the rhythm, the inspiratory 
movement initiation, bodily movement and the route of breathing
  Count clearings of throat, sighs, yawns, and coughs
  Stop observing after 60 s. Note results in the table.
This list of observation items includes features that can define the 
breathing pattern. Karen H. Andreasson developed the list for the 
BEAT DB trial. Version 30 April 2019.
BEAT DB, Breathing Exercises in Asthma Targeting Dysfunctional 
Breathing; RF, respiration frequency.
Inspiratory muscle strength (Maximal Inspiratory Pres-
sure, MIP) will be measured by KH2 (POWER Breathe, 
Southam, Warwickshire, UK).72
Register data from medical records
We will extract medication prescriptions and comor-
bidity at baseline, and medication prescriptions, comor-
bidity, adverse events (AEs; eg, emergency room visits), 
and number of consultations at specialist care respira-
tory nurses and/or pulmonologists from baseline until 
12- month follow- up from electronic medical records.
Adherence
Participants in BrEX +UC group will be asked to complete 
a BrEX home training diary during the 12 weeks of inter-
vention. Number of exercising days and minutes used 
will be described. At sessions 2 and 3, the physiothera-
pist will evaluate the adherence to the home exercise 
programme in a numeric rang scale 1–5 (1=no adher-
ence, 5=excellent adherence). The physiotherapist will 
re- schedule any missed appointments. Good adherence 
with BrEX is defined as completion of three treatment 
sessions.
data management and data monitoring
Data storage follows requirements in GDPR and will be 
kept confident and safe in EasyTrial during and after the 
trial. The Danish Data Protection Agency (REG-55–2016) 
has approved the trial. Only the chief investigator will 
have access to the full dataset. Security is enforced by 
personal password and SMS passcode accompanied with 
limited assignation at different levels of EasyTrial to the 
individual worker. All paper forms are designated pseud-
onyms and transported in code- locked bag to locked file 
cabinet at Naestved Hospital.
All paper- based data will be verified by an independent 
duplicate data entry.
No stopping guidelines are scheduled and no Data 
Monitoring Committee is involved, as the interventions 
and assessments are deemed safe in former trials.
sample size
As argued by Norman et al,73 no universal minimal 
important difference (MID) exists, as MID depends on 
the clinical setting, population and the intervention. 
However, it can often be estimated as half a standard devi-
ation (SD).73 Thomas et al. (breathing exercises vs educa-
tion by a nurse in mild to moderate asthma) found a 0.38 
change in MiniAQLQ score.27
We will use the effect size found in Thomas et al27 as 
MID in our sample calculation (with a calculated SD of 
0.76) and expect to find a similar or higher effect size, 
as (a) BrEX will be an add- on intervention to standard 
specialist care instead of a head- to- head comparison as 
in Thomas et al, and (b) as this secondary care asthma 
population is expected to have a higher disease burden 
due to asthma, that is, greater room for improvement.
There is an inherent risk of the trial being under-
powered because the SD of MiniAQLQ after BrEX in 
secondary care is unknown. However, based on previous 
studies,27 28 we expect that our SD will be sufficient to 
reflect the population.
For the present trial, the sample size needed is 172 to 
detect a 0.38 unit difference between groups in Mini-
AQLQ score (SD of 0.76, power of 90%, and p value of 
0.05 (two- sided)). To allow for drop- outs, we will aim to 
randomise 190 participants.
statistical methods
Analysis of primary and secondary outcomes
Data will be analysed on an intention- to- treat basis, thus 
regardless of protocol adherence, using appropriate 
parametric or non- parametric tests depending on data 
distribution. Primary endpoint (between- group differ-
ence in change in the MiniAQLQ at 6- month follow- up) 
and other continuous variables will be analysed using 
a mixed effects model with subject being a random 
factor and visit (ie, baseline, 3 months and 6 months) 
and treatment arm (BrEX +UC or UC) being fixed 
factors and adjusted for baseline imbalance and treat-
ment centre. These analyses will start in April 2020. Per 
protocol analyses in participant with good adherence 
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will be done. Data at 12 months will be included in 
subsequent secondary analyses of long- term treatment 
results.
Imputations will only be done to explore results of SW, 
and sensitivity analyses (with and with- out imputation) 
will test robustness of these results. We will conduct an 
analysis of SW data to explore the effect of the interven-
tion on PAL, TEE and steps per day.
Secondary analyses include a numbers- needed- to- 
treat (NNT) estimation and trial- specific cut- offs for 
clinically relevant differences in MiniAQLQ (primary 
outcome) to guide the clinical interpretation of the 
results. We will estimate NNT as formula 1/(TER−MER), 
TER being the event rate (proportion of responders, 
ie, participants improving at least corresponding to the 
clinically relevant difference, 0.5 units)49 in the BrEX 
group, and MER the event rate in the usual care group. 
We will calculate the trial- specific MID/responder 
threshold by subtracting the mean MiniAQLQ score 
for those reporting to have experienced a ‘small but 
not important change’ in GPE from those reporting 
‘important change’ in GPE at 6 months.
Both adjusted and unadjusted results will be reported 
including 95% CIs. No interim analyses will be made. 
STATA 15.0 (StataCorp LP) will be used. P values<0.05 will 
be regarded statistically significant. Statistical analyses 
plan will be made publicly available before any analyses 
and unblinding of data.
EthICs, dIssEMInAtIon And PErsPECtIvEs of thE trIAl
Ethics and auditing
Region Zealand Research Ethics Committee approved 
this trial (SJ-552), and it will be conducted in agreement 
with the Helsinki declaration. Written informed consents 
will be obtained from all participants. At the recruitment 
interview, the participants will be informed that if they are 
allocated to usual care group they will be provided physio-
therapy (BrEX) later, given the RCT will find a clinically 
relevant benefit.
Before informed written consent is obtained, potential 
participants will receive written information about the 
trial, after which research team members (nurse or phys-
iotherapist, trained and supervised by chief investigator) 
will inform about the trial and answer any questions from 
the potential trial participant. The Regional Commit-
tees on Health Research Ethics are annually selecting a 
number of trials for auditing. The audit process is inde-
pendent of research groups and sponsors.
Adverse events
We will ask participants about experienced AEs at every 
follow- up using open- probe questions, and record on stan-
dardises forms for reporting and analysis. Additionally, the 
medical records will be checked at 12 months follow- up for 
all AEs occurring during period of trial. We define an AE 
as respiratory events or other events during the trial, which 
may be related to aspects of trial participation leading to 
contact with the GP or hospital. All serious AEs, defined 
as life threatening or resulting in hospitalisation,74 will be 
recorded. If a participant sustains a trial related harm, the 
hospital assurance covers him/her.
dissemination of results and protocol amendments
All results will be published, regardless positive, negative 
or inconclusive, in peer- reviewed journals in due time after 
trial completion and to follow the Consolidated Standards 
of Reporting Trials (CONSORT) statement.52
Exclusion criteria were modified on first of March 2018 
when (a) other known cause of dyspnoea (eg, cardiovas-
cular disease, other respiratory disease) and (b) neurolog-
ical disease (cannot follow an instruction or close lips) were 
deleted.
Any important protocol modification will be reported 
to the Ethics Committee for approval, and they will be 
registered at  ClinicalTrials. gov.
Perspective and additional knowledge for clinical practice
The present trial will provide evidence of the effectiveness 
of the BrEX programme in patients with incomplete asthma 
control despite attending specialist care and adhering to 
moderate to high doses inhaled corticosteroids (ICS) with/
without a second controller (GINA steps 3–5).2 Asthma 
control is not obtained in the majority of patients,14 75 76 and 
new measures to improve patients’ daily life with asthma 
are needed. The trial results will add pivotal information 
to future evidence- based guidelines and clinical practice. 
Although primarily an effectiveness trial, we will also gain 
potential insights into the characteristics of responders and 
into the mechanisms of effectiveness. In particular, we will 
explore the predictive value of reduced BHT, comorbid 
anxiety and depression (HADS), socioeconomic status, 
smoking status, and PAL at baseline.
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